ConductScience.org, home

Paper40326484

Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis.

Chen S and 5 others. J Clin Pharmacol, 2025. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis. Papers, record 40326484. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40326484

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Can Methotrexate Monotherapy Achieve Clinical Remission in Patients with Active Rheumatoid Arthritis? A Model-Based Meta-Analysis.
PubMed
Journal
J Clin Pharmacol
PubMed
Year
2025
PubMed
Publication types
Journal Article, Meta-Analysis, Systematic Review, Research Support, Non-U.S. Gov't
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-06-02
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Chen SShengyanghttps://orcid.org/0009-0001-5473-6879
2Wu YYangrui
3Huang WWei
4Zhou JJianxing
5Wei ZZipeng
6Wu XXuemeihttps://orcid.org/0000-0003-1640-7385

Source PubMed

Download CSV of authors

Topics9

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
MethotrexateMajor topic
Arthritis, RheumatoidMajor topic
Antirheumatic AgentsMajor topic
Humans
Remission Induction
Randomized Controlled Trials as Topic
Treatment Outcome
C-Reactive Protein
Blood Sedimentation

Source PubMed

Download CSV of topics

References93

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137180723The effect of JuanBiQiangGu granules in combination with methotrexate on joint inflammation in rheumatoid arthritis: a randomized controlled trial.Front Pharmacol2023https://conductscience.org/library/papers/37180723PubMed
223053688
A multicenter, randomized, double-blind clinical trial of combination therapy with Anbainuo, a novel recombinant human TNFRII:Fc fusion protein, plus methotrexate versus methotrexate alone or Anbainuo alone in Chinese patients with moderate to severe rheumatoid arthritis.
Clin Rheumatol2013https://conductscience.org/library/papers/23053688PubMed
310573044Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group.Arch Intern Med1999https://conductscience.org/library/papers/10573044PubMed
423294500Tofacitinib (CP-690,550) in combination with methotrexate in patients with active rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitors: a randomised phase 3 trial.Lancet2013https://conductscience.org/library/papers/23294500PubMed
515641102
Very early treatment with infliximab in addition to methotrexate in early, poor-prognosis rheumatoid arthritis reduces magnetic resonance imaging evidence of synovitis and damage, with sustained benefit after infliximab withdrawal: results from a twelve-month randomized, double-blind, placebo-controlled trial.
Arthritis Rheum2005https://conductscience.org/library/papers/15641102PubMed
611096165A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.N Engl J Med2000https://conductscience.org/library/papers/11096165PubMed
736642813Model-based meta-analysis of non-small cell lung cancer with standard of care PD-1 inhibitors and chemotherapy for early development decision making.CPT Pharmacometrics Syst Pharmacol2023https://conductscience.org/library/papers/36642813PubMed
817235556Preliminary evaluation in rheumatoid arthritis activity in patients treated with TNF-alpha blocker plus methotrexate versus methotrexate or leflunomide alone.Rheumatol Int2007https://conductscience.org/library/papers/17235556PubMed
932907614The multi-biomarker disease activity test for assessing response to treatment strategies using methotrexate with or without prednisone in the CAMERA-II trial.Arthritis Res Ther2020https://conductscience.org/library/papers/32907614PubMed
1026139202Efficacy and safety evaluation of a combination of iguratimod and methotrexate therapy for active rheumatoid arthritis patients: a randomized controlled trial.Clin Rheumatol2015https://conductscience.org/library/papers/26139202PubMed
1119369462Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis.J Rheumatol2009https://conductscience.org/library/papers/19369462PubMed
1219180516Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.Arthritis Rheum2009https://conductscience.org/library/papers/19180516PubMed
1324976447Randomized controlled trial comparing 2 different starting doses of methotrexate in rheumatoid arthritis.Clin Ther2014https://conductscience.org/library/papers/24976447PubMed
1412154206
Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years.
Rheumatology (Oxford)2002https://conductscience.org/library/papers/12154206PubMed
1522739990
Induction therapy with adalimumab plus methotrexate for 24 weeks followed by methotrexate monotherapy up to week 48 versus methotrexate therapy alone for DMARD-naive patients with early rheumatoid arthritis: HIT HARD, an investigator-initiated study.
Ann Rheum Dis2013https://conductscience.org/library/papers/22739990PubMed
169374925Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: a randomized, controlled, double-blind, 52 week clinical trial.Br J Rheumatol1997https://conductscience.org/library/papers/9374925PubMed
1723011358
A phase 3 randomized, double-blind, multicenter comparative study evaluating the effect of etanercept versus methotrexate on radiographic outcomes, disease activity, and safety in Japanese subjects with active rheumatoid arthritis.
Mod Rheumatol2013https://conductscience.org/library/papers/23011358PubMed
1831908843Correction: Abatacept in combination with methotrexate in Japanese biologic-naive patients with active rheumatoid arthritis: a randomised placebo-controlled phase IV study.RMD Open2019https://conductscience.org/library/papers/31908843PubMed
1922012969Sustained inhibition of progressive joint damage with rituximab plus methotrexate in early active rheumatoid arthritis: 2-year results from the randomised controlled trial IMAGE.Ann Rheum Dis2012https://conductscience.org/library/papers/22012969PubMed
2037377385Tofacitinib versus methotrexate as the first-line disease-modifying antirheumatic drugs in the treatment of rheumatoid arthritis: An open-label randomized controlled trial.Int J Rheum Dis2023https://conductscience.org/library/papers/37377385PubMed

See all 93 referencesDownload CSV of references

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CRP1401PubTator's text mininghttps://conductscience.org/library/genes/1401

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Cited by
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/40326484

GET https://conductscience.org/api/papers/v1/40326484/references?page=2